Literature DB >> 19501856

Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life.

John A Morrison1, Charles J Glueck, Paul S Horn, Samrat Yeramaneni, Ping Wang.   

Abstract

To assess relationships between pediatric lipids and subsequent cardiovascular disease (CVD) in the fourth to fifth decades, we conducted 22- to 31-year follow-up studies (1998-2003) in former schoolchildren first studied in 1973-1976. The follow-up included 53% of eligible former subjects. We compared pediatric and adult body mass (in kilograms per square meter) and lipids in 19 cases with at least 1 CVD event and in 789 CVD event-free subjects. Mean +/- SD age was 12.3 +/- 3.3 years at entry and 38.5 +/- 3.8 years at follow-up. Mean age at the first CVD event was 37.1 +/- 4.9 years. The major novel finding of our study was that childhood triglycerides (TG) were consistently and independently associated with young adult CVD. The distributions of both childhood and adult TG were shifted to higher levels in the cases than controls. Of the 19 cases, 7 (37%) had childhood TG greater than the pediatric 95th percentile (153 mg/dL); and 6 of these 7 had high TG (>/=150 mg/dL) at adult follow-up. Overall, 61% of cases had high TG as adults. After adjusting for age, sex, and race, by analysis of variance, cases had higher TG levels both in childhood and in young adulthood. A bootstrapping method and the Cox proportional hazard analysis were used to predict CVD in the cohort with explanatory variables sex; race; childhood body mass index, low-density lipoprotein, log high-density lipoprotein cholesterol, and log TG; and adult cigarette smoking and type 2 diabetes mellitus. Childhood TG level was a significant, independent explanatory variable for young adult CVD hazard (hazard ratio, 5.35; 95% confidence interval, 1.69-20.0 for each 1-unit increase in natural logarithm scale) along with adult type 2 diabetes mellitus (hazard ratio, 19.4; 95% confidence interval, 4.24-114.2). Pediatric hypertriglyceridemia appears to be a significant, independent, potentially reversible correlate of young adult CVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501856      PMCID: PMC2774112          DOI: 10.1016/j.metabol.2009.04.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  54 in total

1.  Risk factors for subclinical carotid atherosclerosis in healthy men.

Authors:  Frank Weber
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

2.  Plasma cholesterol and triglyceride levels in 6,775 school children, ages 6--17.

Authors:  J A Morrison; I deGroot; B K Edwards; K A Kelly; J L Rauh; M Mellies; C J Glueck
Journal:  Metabolism       Date:  1977-11       Impact factor: 8.694

3.  Populations and methods for assessing dyslipoproteinemia and its correlates. The Lipid Research Clinics Program Prevalence Study.

Authors:  O D Williams; S Stinnett; L E Chambless; K E Boyle; P S Bachorik; J J Albers; K Lippel
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

4.  Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study.

Authors:  P H Davis; J D Dawson; W A Riley; R M Lauer
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

7.  Lipid and lipoprotein tracking in children.

Authors:  P Laskarzewski; J A Morrison; I deGroot; K A Kelly; M J Mellies; P Khoury; C J Glueck
Journal:  Pediatr Res       Date:  1979-09       Impact factor: 3.756

8.  Stability of variables associated with the metabolic syndrome from adolescence to adulthood: the Aerobics Center Longitudinal Study.

Authors:  Joey C Eisenmann; Gregory J Welk; Eric E Wickel; Steven N Blair
Journal:  Am J Hum Biol       Date:  2004 Nov-Dec       Impact factor: 1.937

9.  Relationships of measurements of body mass to plasma lipoproteins in schoolchildren and adults.

Authors:  P Laskarzewski; J A Morrison; M J Mellies; K Kelly; P S Gartside; P Khoury; C J Glueck
Journal:  Am J Epidemiol       Date:  1980-04       Impact factor: 4.897

10.  Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study.

Authors:  Joanne M Murabito; Byung-Ho Nam; Ralph B D'Agostino; Donald M Lloyd-Jones; Christopher J O'Donnell; Peter W F Wilson
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

View more
  20 in total

1.  Cohort Profile: the international childhood cardiovascular cohort (i3C) consortium.

Authors:  Terence Dwyer; Cong Sun; Costan G Magnussen; Olli T Raitakari; Nicholas J Schork; Alison Venn; Trudy L Burns; Markus Juonala; Julia Steinberger; Alan R Sinaiko; Ronald J Prineas; Patricia H Davis; Jessica G Woo; John A Morrison; Stephen R Daniels; Wei Chen; Sathanur R Srinivasan; Jorma Sa Viikari; Gerald S Berenson
Journal:  Int J Epidemiol       Date:  2012-03-20       Impact factor: 7.196

Review 2.  Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review.

Authors:  Emily Rothbaum Perito; Audrey Lau; Sue Rhee; John P Roberts; Philip Rosenthal
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

3.  Childhood risk factors predict cardiovascular disease, impaired fasting glucose plus type 2 diabetes mellitus, and high blood pressure 26 years later at a mean age of 38 years: the Princeton-lipid research clinics follow-up study.

Authors:  John A Morrison; Charles J Glueck; Ping Wang
Journal:  Metabolism       Date:  2011-10-14       Impact factor: 8.694

4.  Long-Term Effects of Childhood Risk Factors on Cardiovascular Health During Adulthood.

Authors:  Roman Shrestha; Michael Copenhaver
Journal:  Clin Med Rev Vasc Health       Date:  2015-08-12

5.  Pediatric non-high-density lipoprotein cholesterol, the metabolic syndrome, and insulin resistance.

Authors:  Charles J Glueck; John A Morrison
Journal:  J Pediatr       Date:  2010-10-29       Impact factor: 4.406

6.  Prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes in Austria.

Authors:  Claudia Steigleder-Schweiger; Birgit Rami-Merhar; Thomas Waldhör; Elke Fröhlich-Reiterer; Ines Schwarz; Maria Fritsch; Martin Borkenstein; Edith Schober
Journal:  Eur J Pediatr       Date:  2012-03-16       Impact factor: 3.183

7.  The child as proband for future parental cardiometabolic disease: the 26-year prospective Princeton Lipid Research Clinics Follow-up Study.

Authors:  John A Morrison; Charles J Glueck; Ping Wang
Journal:  J Pediatr       Date:  2012-01-13       Impact factor: 4.406

8.  Consumption of added sugars and indicators of cardiovascular disease risk among US adolescents.

Authors:  Jean A Welsh; Andrea Sharma; Solveig A Cunningham; Miriam B Vos
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

9.  Usual intake of added sugars and lipid profiles among the U.S. adolescents: National Health and Nutrition Examination Survey, 2005-2010.

Authors:  Zefeng Zhang; Cathleen Gillespie; Jean A Welsh; Frank B Hu; Quanhe Yang
Journal:  J Adolesc Health       Date:  2015-03       Impact factor: 5.012

Review 10.  Pediatric Markers of Adult Cardiovascular Disease.

Authors:  Micah Olson; Melissa Chambers; Gabe Shaibi
Journal:  Curr Pediatr Rev       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.